Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder

@article{Liebowitz2017VortioxetineVP,
  title={Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder},
  author={Michael R. Liebowitz and Jason Careri and Kyra Blatt and Ann Draine and Junko Morita and Melissa Moran and Rita Hanover},
  journal={Depression and Anxiety},
  year={2017},
  volume={34},
  pages={1164 - 1172}
}
Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo‐controlled treatment trials. This study reports a trial of vortioxetine, an antidepressant that has also shown benefit in Generalized Anxiety Disorder (GAD), in patients meeting DSM‐5 criteria for both MDD and SAD. 

Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges

In this review, major psychiatric comorbidities that can be encountered over the course of SAD as well asComorbidity associated diagnostic and therapeutic challenges will be discussed.

Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.

In routine clinical practice, vortioxetine was associated with clinically meaningful, sustained improvements in functioning, and depressive and cognitive symptoms, in patients with MDD and co-morbid GAD.

Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan

Vortioxetine may be effective for patients with anxiety symptoms in MDD and further research is warranted to investigate these effects in a real-world clinical setting.

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

These results demonstrate the effectiveness and tolerability of vortioxetine for the treatment of MDD in a large and heterogeneous patient population representative of that encountered in routine clinical practice.

Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study

Treatment with vortioxetine was associated with long-term improvement in clinical symptoms and measures of work productivity in patients with MDD in a real-world setting, irrespective of severity of anxiety symptoms at the start of treatment.

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment

Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD.

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study

Clinically relevant and sustained improvements in overall functioning, symptoms of depression, cognitive symptoms, and health-related quality of life were observed in patients with MDD treated with vortioxetine over a period of 6 months in routine care in Italy, including a high proportion of elderly patients.

Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial

Investigation of the effects of vortioxetine on sleep quality and association between changes in sleep and treatment response found improvements in sleep were predictive of antidepressant response and were linearly correlated with improvement in overall depressive symptom severity.

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study

Clinically relevant and sustained improvements in overall functioning, depressive symptoms, cognitive symptoms, and cognitive performance were observed in patients with MDD treated with vortioxetine for 6 months in routine clinical practice settings in France.

References

SHOWING 1-10 OF 31 REFERENCES

Citalopram treatment of social anxiety disorder with comorbid major depression

Improvement in social anxiety disorder symptoms lagged behind improvement in depression, and greater than 12 weeks of treatment may be required to assess full social anxiety response in patients with comorbid depression.

Pharmacological treatment of social anxiety disorder.

Proof-of-concept and other preliminary studies suggest the efficacy of psychotherapy can be enhanced through prior administration of D-cycloserine, cannabidiol, or oxytocin, and it is unlikely that combining pharmacotherapy with psychotherapy results in greater overall efficacy compared to either treatment given alone.

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

Venlafaxine ER is safe, well tolerated, and efficacious in the short-term treatment of generalized social anxiety disorder.

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.

Paroxetine is an effective treatment for patients with generalized social phobia and short-term treatment results in substantial and clinically meaningful reductions in symptoms and disability.

Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults.

The presence of comorbid SAD in adolescents who are already depressed is associated with a more malignant course and character of subsequent depressive illness, and social anxiety disorder during adolescence or young adulthood is an important predictor ofsequent depressive disorders.

A randomised, double‐blind, placebo‐controlled, duloxetine‐referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder

This study aims to evaluate the efficacy and tolerability of vortioxetine 2.5‐, 5‐ and 10‐mg once‐daily doses vs. placebo in the treatment of generalised anxiety disorder (GAD).

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.

Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.

Pharmacological treatment of social anxiety disorder: A meta‐analysis

The stability of the SSRI effect size estimate in conjunction with other evidence for safety and tolerability and their ability to treat comorbid conditions supports the use of SSRIs as the first‐line treatment.